Analysis of research trends and hotspots of Tripterygium wilfordii multiglucoside in recent 20 years based on knowledge graph
WANG Hongyun1 TU Sijie1 WANG Xiaoqin2,3 ZOU Xinrong2,3
1.Clinical College of Traditional Chinese Medicine, Hubei University of Chinese Medicine, Hubei Province, Wuhan 430061, China;
2.Department of Nephrology, Hubei Provincial Hospital of Traditional Chinese Medicine, Hubei Province, Wuhan 430061, China;
3.Institute of Nephrology, Hubei Province Academy of Traditional Chinese Medicine, Hubei Province, Wuhan 430074, China
Abstract：Objective To explor the research trend and progress around the theme of “Tripterygium wilfordii multiglucoside (TWM)” in China in the past 20 years by bibliometric visualization analysis. Methods All literatures directly related to TWM included in CNKI database from January 2000 to August 2020 were as the research object, combined with software such as CiteSpace and Vosviewer, the publication trends, journals, institutions, authors and keywords were analyzed and the corresponding knowledge map was drawed. Results A total of 1715 qualified literatures were screened and published in 386 related academic journals. Frequency statistics and collaborative network analysis revealed that 4047 researchers from 1846 institutions participated in TWM related studies. Key words analysis result showed that renal diseases, rheumatic immune diseases and immune-related skin diseases were the key areas of TWM research and application. In addition, the pharmacological effects and adverse drug reactions of TWM were also the focus of scholars’ attention. Conclusion TWM has been paid more and more attention by scholars, but the further cooperation between agencies and teams still needs to be strengthened. In the future, the research and application of TWM in nephrology, rheumatology and dermatology are worthy of further exploration.
王虹云1 涂思洁1 王小琴2,3 邹新蓉2,3. 基于知识图谱分析近20年雷公藤多苷的研究趋势与热点[J]. 中国医药导报, 2021, 18(17): 18-24.
WANG Hongyun1 TU Sijie1 WANG Xiaoqin2,3 ZOU Xinrong2,3. Analysis of research trends and hotspots of Tripterygium wilfordii multiglucoside in recent 20 years based on knowledge graph. 中国医药导报, 2021, 18(17): 18-24.
[1] 姜开运，任艳玲.基于“从肾论治”之《神农本草经》药物探究[J].北京中医药，2011，30（12）：912-915.
[2] 昊霞，林兵，王忠震，等.雷公藤的免疫抑制活性及毒性的谱效关系研究[J].中国医院药学杂志，2016，36（7）：547-552.
[3] 周超峰.文献计量常用软件比较研究[D].武汉：华中师范大学，2017.
[4] Chen C. Searching for intellectual turningpoints：progressive knowledge domain visualization [J]. Proc Natl Acad Sci U S A，2004，101Suppl1：5303-5310.
[5] Chen C. CiteSpaceⅡ：Detecting and visualizing emerging trends and transient pattern sinscientific literature [J]. Journal of the China Society for Scientific and Technical Information，2006，57（3）：359-377.
[6] 汪靓雯.雷公藤多苷联合激素治疗过敏性紫癜性肾炎的系统评价和Meta分析[D].武汉：湖北中医药大学，2019.
[7] 张梦久，柳红芳，郭燕，等.雷公藤多苷治疗糖尿病肾脏病临床疗效及安全性的Meta分析[J].医学综述，2020， 26（9）：1828-1836.
[8] 刘奎，张媛.雷公藤多苷联合ACEI/ARB类药物治疗糖尿病肾病有效性和安全性系统评价[J].中医药临床杂志，2019，31（11）：2086-2091.
[9] 朱国双，王岚，龙清华，等.雷公藤多苷对比RAAS阻滞剂治疗糖尿病肾脏病有效性和安全性的Meta分析[J].临床肾脏病杂志，2019，19（10）：727-733.
[10] 陈文佳，李泰贤，王晓月，等.雷公藤多苷（甙）片单用或联用甲氨蝶呤治疗类风湿关节炎临床疗效RCT研究的Meta分析[J].中国中药杂志，2020，45（4）：791-797.
[11] Yang YJ，Deng Y，Liao LL，et al. Tripterygium Glycosides Combined with Leflunomide for Rheumatoid Arthritis：A Systematic Reviewand Meta-Analysis [J]. EvidBased Complement Alternat Med，2020，2020：1230320.
[12] 何彦瑶，赵昕，张羽，等.雷公藤多苷治疗IgA肾病疗效及安全性的Meta分析[J].中国中西医结合肾病杂志，2019，20（9）：794-799.
[13] 刘琪华.雷公藤多苷治疗特发性膜性肾病的Meta分析[D].吉林：长春中医药大学，2019.
[14] Zhan H，Jin J，Liang S，et al. Tripterygium glycoside protects diabetic ki dney disease mouse serum-induced podocyte injury by upregulating autophagy and downregulating beta-arrestin-1 [J]. Histol Histopathol，2019，34（8）：943-952.
[15] 徐百升，夏璐，胡春艳.雷公藤多苷对链脲佐菌素诱导糖尿病肾病大鼠糖基化终末产物特异性受体/细胞核因子-κB信号通路的影响[J].成都医学院学报，2018， 13（3）：262-265.
[16] Chen F，Ma YL，Ding H，et al. Effects of Tripterygium wilfordii glycosides on regulatory Tcells and Th17 in an IgA nephropathy rat mode l[J]. Genet Mol Res，2015，14（4）：14900-14907.
[17] Gong J，Jin J，Zhao L，et al. Tripterygium glycoside protects against puromycin amino nucleosideinduced podocyte injury by upregulating autophagy [J]. Int J Mol Med，2018，42（1）：115-122.
[18] 袁薪蕙，王保和，杜犀.雷公藤多苷片治疗肾病综合征作用机制的网络药理学研究[J].现代药物与临床，2019，34（11）：3209-3214.
[19] 朱俊利，毛永炎.雷公藤多苷联合贝那普利对老年原发性肾病综合征病人肾功能及血清免疫球蛋白水平的影响[J].安徽医药，2020，24（1）：179-183.
[20] 张倩.雷公藤多苷联合雷米普利治疗老年原发性肾病综合征的疗效[J].中国合理用药探索，2019，16（12）：58-61.
[21] Liu S，Li X，Li H，et al. Comparison of tripterygium wilfordii multiglycosides and tacrolimus in the treatment of idiopathic membranous nephropathy: a prospective cohort study [J]. BMC Nephrol，2015，16：200.
[22] Ren D，Zuo C，Xu G. Clinical efficacy and safety of Tripterygium wilfordii Hook in the treatment of diabetic kidney disease stage Ⅳ: A meta-analysis of randomized controlled trials [J]. Medicine (Baltimore)，2019，98（11）：e14604.
[23] 叶冠成，陈光耀，江雯欣，等.类风湿关节炎动物模型研究进展[J].安徽中医药大学学报，2019，38（5）：88-92.
[24] 李逸群，胡瑞学，贾可欣，等.雷公藤多苷（甙）片治疗类风湿关节炎的安全性系统评价[J].中国中药杂志，2020， 45（4）：775-790.
[25] Wang J，Chu Y，Zhou X. Inhibitory effect of Triperygium wilfordii polyglucoside on dipeptidyl peptidase Ⅰ in vivo and in vitro [J]. Biomed Pharmacother，2017，96：466-470.
[26] 张学美，向双梅.口服雷公藤多苷片治疗寻常型银屑病的临床随机试验Meta分析[J].中国医药指南，2013， 11（27）：392-393.
[27] Zhao J，Di T，Wang Y，et al. Multi-glycoside of Tripterygium wilfordii Hook. f. ameliorates imiquimod-induced skin lesions through a STAT3-dependent mechanism involving the inhibition of Th17-mediated inflammatory responses [J]. Int J Mol Med，2016，38（3）：747-757.
[28] 何康婧，高增平，尹丽梅，等.雷公藤多苷的药理毒理作用研究进展[J].中国实验方剂学杂志，2020，26（1）：196-204.
京公网安备 11010502046598号